Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization

Im Fokus Onkologie · Springer Nature · 2026-11-19 · DOI: 10.1007/s00221-026-07431-6

Аннотация

This study investigated whether asperuloside (ASP) regulates microglial metabolic reprogramming and polarization via AMPK signaling to protect dopaminergic neurons in Parkinson’s disease (PD). In LPS-stimulated BV-2 microglia, ASP reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), decreased the CD86/CD206 ratio, upregulated M2 markers ( Arg1 , Chil3 , Retnla ) and enhanced the activities of SOD, CAT, and GPx. ASP shifted metabolism from glycolysis to oxidative phosphorylation (reduced ECAR/lactate, restored OCR/ATP, upregulated Ppargc1a / Nrf1 ), accompanied by increased AMPK phosphorylation and reduced NF-κB activation; these effects were partially blocked by dorsomorphin (AMPK inhibitor). Conditioned media from ASP-treated microglia improved MN9D neuronal viability, reduced apoptosis, and increased PSD95/SYP. In MPTP-treated mice, ASP improved motor function, reduced α-synuclein aggregation, increased TH + neurons, restored striatal dopamine and its metabolites (DOPAC and HVA), and decreased M1 microglia and pro-inflammatory cytokines in the substantia nigra. Collectively, these findings suggest that ASP modulates microglial metabolism and polarization, at least in part through the AMPK/NF-κB signaling, contributing to neuroprotection in PD.

Читать у издателя →

Похожие статьи